Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS

NCT05602142 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT05602142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05602142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS
Lead sponsor
Johns Hopkins University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
July 31, 2027
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

als